An Innovative Polymeric Platform for Controlled and Localized Drug Delivery

Monica Elbjorn, Jacob Provencio, Paige Phillips, Javier Gutiérrez Sainz, Nathanael Harrison, David Di Rocco, Ada Jaramillo, Priya Jain, Alejandro Lozano, R. Lyle HoodPharmaceutics 2023 · DOI

TL;DR

Researchers have developed a novel, implantable polymeric drug delivery system (PCRS) designed for controlled and localized drug release over several weeks. This system, fabricated using biodegradable polymers like PCL and PLA, offers a promising alternative to traditional drug administration methods, potentially improving treatment efficacy and patient adherence for conditions like cervical cancer.

What Problem Does This Paper Address?

The paper tackles the persistent challenges in treating advanced or recurrent cervical cancer, where current treatment regimens (radiotherapy and chemotherapy) often struggle with efficacy and significant side effects. While localized drug delivery of agents like cisplatin shows promise, existing methods lack a sophisticated, tunable system for sustained and controlled release. Oral and injectable routes face issues with bioavailability, first-pass metabolism, and patient adherence. The authors aim to bridge this gap by developing an implantable system that can deliver drugs precisely where needed, over an extended period, and with customizable release profiles.

Methods

The core innovation lies in the development of the Polymeric Controlled Release System (PCRS). Key methodological aspects include:

  • Material Selection: Biodegradable polymers polycaprolactone (PCL) and polylactic acid (PLA) were chosen for their biocompatibility and FDA approval for implantable devices. PCL was selected for its malleability and lower melting point, while PLA was explored for its thermoplastic properties.
  • Drug Analog: Rhodamine B (RhB) was used as a fluorescent tracer to mimic the behavior of hydrophilic drugs like cisplatin, allowing for easy detection and quantification of release.
  • Manufacturing: A novel injection mold technique was developed for batch manufacturing of PCRS devices. This process allowed for the creation of reproducible geometries with tight tolerances.
  • Geometry Design: Four distinct geometries were designed and fabricated: a solid sphere, a sphere with a through-hole, a cylindrical rod, and a cylindrical tube. This variation was intended to explore the impact of surface area and shape on drug release.
  • In Vitro Release Studies: Release kinetics were studied in phosphate-buffered saline (PBS) at 37°C. Experiments included:
  • Mixture Homogeneity: Testing the uniform distribution of RhB within the polymer matrix.
  • Initial Release Burst: Characterizing the immediate release profile over the first 12 hours.
  • Single Spherical Device Release: Assessing long-term release (21 days) from PCL and PLA spheres.
  • Geometry Variance: Evaluating the effect of different device shapes on release rates over 21 days.
  • Characterization: Techniques like UV-Vis spectroscopy were used for RhB quantification, and Focused Ion Beam-Scanning Electron Microscopy (FIB-SEM) was employed to visualize the RhB particles within the polymer matrix and assess homogeneity.

Datasets

Not discussed in the paper. The study relies on in vitro experimental data generated from the fabricated PCRS devices.

Key Insights and Ideas

  • Tunable Release via Geometry: The most significant insight is that the release rate of RhB from the PCRS devices is directly proportional to the device's surface area. This suggests that by carefully designing the geometry of the implant, the drug release profile can be tailored to specific therapeutic needs.
  • Biphasic Release Profile: Both PCL-based spherical devices and the split-section homogeneity tests demonstrated a biphasic release pattern: an initial burst release followed by a sustained, incremental release. This is a desirable characteristic for many drug delivery applications, allowing for an immediate therapeutic effect and prolonged action.
  • PCL's Promise for Sustained Release: PCL-based devices showed consistent and sustained release over 21 days, indicating their potential as a viable platform for long-term drug delivery.
  • PLA's Limited In Vitro Release: In contrast, PLA-based spherical devices showed negligible release in vitro over the 21-day period. While this limits its immediate utility as a standalone release matrix in this study, the authors suggest that PCL-PLA composites could offer a way to control aqueous access and modulate release.
  • Homogenous Drug Distribution: FIB-SEM analysis confirmed that RhB was homogenously distributed within the PCL matrix, which is crucial for predictable and consistent drug release.

Key Results

  • Reproducible Fabrication: The injection mold technique successfully produced reproducible PCRS devices within tight dimensional tolerances (+/- 100 µg).
  • Homogeneous Mixture: FIB-SEM analysis indicated approximately 25% RhB particles within the selected surface area of PCL spheres, suggesting a thorough and homogenous mixture.
  • PCL Release Profile: PCL spheres exhibited an initial burst release (0.04% of total loaded drug on day 1) followed by a sustained release phase, achieving a cumulative release of approximately 0.08% of total loaded drug over 21 days. A linear regression of days 1-21 showed a high R² value (0.9963).
  • Geometry-Dependent Release:
    • The PCRS cylindrical tube (largest surface area, 48.387 mm²) achieved the highest cumulative RhB release (42.068 µg) over 21 days.
  • The PCRS sphere (smallest surface area, 12.968 mm²) showed the lowest release (5.079 µg) over 21 days.
  • All geometries demonstrated a biphasic release pattern with high R² values for linear regression.
  • PLA In Vitro Performance: PLA devices showed no significant release in vitro over the 21-day period.

Limitations and Future Work

  • In Vitro vs. In Vivo: The study was conducted entirely in vitro. The authors acknowledge that results may differ significantly in vivo due to factors like differences in biological fluids, subject movement, and local tissue perfusion.
  • Sink Solution Evaporation: Variations in sink solution evaporation during sampling were noted as a potential source of error.
  • Limited Drug Analog: Only Rhodamine B was tested as a drug analog. Future work should explore the combination of different polymer composites and a wider range of drug types.
  • PLA Release: The lack of in vitro release from PLA devices suggests the need for further investigation into composite materials or longer-term degradation studies to unlock its potential.
  • Future Directions: The authors propose introducing the polymeric implant into targeted tumor cavities in vivo (specifically the cervix) to replicate anatomical structures and evaluate the efficacy of local drug delivery. This would be a crucial next step in validating the PCRS platform for therapeutic applications. They also suggest exploring multistage polymer drug delivery systems for personalized loading and maintenance phases.

Summary updated

Abstract

Precision medicine aims to optimize pharmacological treatments by considering patients' genetic, phenotypic, and environmental factors, enabling dosages personalized to the individual. To address challenges associated with oral and injectable administration approaches, implantable drug delivery systems have been developed. These systems overcome issues like patient adherence, bioavailability, and first-pass metabolism. Utilizing new combinations of biodegradable polymers, the proposed solution, a Polymeric Controlled Release System (PCRS), allows minimally invasive placement and controlled drug administration over several weeks. This study's objective was to show that the PCRS exhibits a linear biphasic controlled release profile, which would indicate potential as an effective treatment vehicle for cervical malignancies. An injection mold technique was developed for batch manufacturing of devices, and in vitro experiments demonstrated that the device's geometry and surface area could be varied to achieve various drug release profiles. This study's results motivate additional development of the PCRS to treat cervical cancer, as well as other malignancies, such as lung, testicular, and ovarian cancers.
BibTeX
@inproceedings{elbjorn2023innovative,
  author = {Monica Elbjorn and Jacob Provencio and Paige Phillips and Javier Gutiérrez Sainz and Nathanael Harrison and David Di Rocco and Ada Jaramillo and Priya Jain and Alejandro Lozano and R. Lyle Hood},
  title = {{An Innovative Polymeric Platform for Controlled and Localized Drug Delivery}},
  booktitle = {Pharmaceutics},
  year = {2023},
  doi = {10.3390/pharmaceutics15071795},
}
Figure